biontech
pfizer
initiate
rolling
submission
european
medicines
agency
vaccine
candidate
rolling
review
accepted
ema
based
available
preclinical
clinical
data
date
biontech
pfizer
continue
regular
open
dialogue
ema
providing
results
ongoing
phase
study
new
york
mainz
germany
october
pfizer
nyse
pfe
biontech
se
nasdaq
bntx
today
announced
initiation
rolling
submission
european
medicines
agency
ema
lead
candidate
companies
vaccine
development
program
ema
decision
start
rolling
review
follows
encouraging
preliminary
results
early
clinical
studies
adults
suggest
triggers
production
neutralizing
antibodies
dominant
cells
target
combination
antibody
cell
response
believed
important
eliciting
protection
viral
infection
disease
biontech
pfizer
plan
work
ema
committee
medicinal
products
human
use
chmp
complete
rolling
review
process
facilitate
final
marketing
authorization
application
maa
part
rolling
review
chmp
begun
evaluating
data
generated
trials
formal
maa
submission
could
finalized
following
rolling
review
process
pending
demonstration
vaccine
efficacy
safety
confirmation
ema
submitted
data
adequate
vaccine
candidate
remain
subject
ema
diligent
standards
quality
safety
efficacy
duty
ensure
working
develop
potential
vaccine
unprecedented
speed
help
address
pandemic
highest
ethical
standards
adhering
sound
scientific
principles
continue
regular
open
dialogue
ema
throughout
rolling
review
process
said
ugur
sahin
ceo
biontech
global
crisis
magnitude
completely
transformed
vaccine
development
review
process
said
peter
honig
senior
vice
president
head
worldwide
safety
regulatory
pfizer
making
every
effort
develop
safe
effective
vaccine
following
guidance
regulatory
agencies
proud
take
historic
step
european
medicines
agency
vaccine
candidate
vaccine
candidate
based
biontech
proprietary
mrna
technology
supported
pfizer
global
vaccine
development
manufacturing
capabilities
encodes
optimized
spike
glycoprotein
target
virus
neutralizing
antibodies
vaccine
candidate
currently
evaluated
global
phase
study
ongoing
clinical
sites
worldwide
including
united
states
brazil
south
africa
argentina
date
trial
enrolled
approximately
participants
received
second
vaccination
preliminary
data
phase
portions
study
demonstrated
well
tolerated
mild
moderate
adverse
events
age
groups
vaccine
candidate
generated
dose
immunogenicity
measured
receptor
binding
domain
rbd
igg
concentrations
neutralizing
titers
addition
human
participants
displayed
favorable
breadth
epitopes
recognized
cell
responses
specific
spike
antigen
demonstrated
concurrent
induction
high
magnitude
cell
responses
dominant
rbd
remainder
full
spike
glycoprotein
full
information
previously
released
data
found
information
ongoing
phase
trial
visit
using
number
ema
rolling
review
normally
data
investigational
medicine
efficacy
safety
quality
required
documents
must
submitted
start
evaluation
complete
application
marketing
authorization
case
rolling
review
ema
chmp
reviews
data
become
available
ongoing
studies
complete
application
submitted
chmp
decides
sufficient
data
available
complete
application
submitted
company
reviewing
data
become
available
chmp
reach
opinion
sooner
whether
investigational
medicine
vaccine
authorized
positive
opinion
adopted
chmp
european
commission
role
grant
marketing
authorization
pfizer
breakthroughs
change
patients
lives
pfizer
apply
science
global
resources
bring
therapies
people
extend
significantly
improve
lives
strive
set
standard
quality
safety
value
discovery
development
manufacture
health
care
products
including
innovative
medicines
vaccines
every
day
pfizer
colleagues
work
across
developed
emerging
markets
advance
wellness
prevention
treatments
cures
challenge
feared
diseases
time
consistent
responsibility
one
world
premier
innovative
biopharmaceutical
companies
collaborate
health
care
providers
governments
local
communities
support
expand
access
reliable
affordable
health
care
around
world
years
worked
make
difference
rely
us
routinely
post
information
may
important
investors
website
addition
learn
please
visit
us
follow
us
twitter
pfizer
pfizer
news
linkedin
youtube
like
us
facebook
pfizer
pfizer
disclosure
notice
information
contained
release
october
pfizer
assumes
obligation
update
statements
contained
release
result
new
information
future
events
developments
release
contains
information
pfizer
efforts
combat
collaboration
biontech
pfizer
develop
potential
vaccine
mrna
vaccine
program
modrna
candidate
including
qualitative
assessments
available
data
potential
benefits
expectations
clinical
trials
anticipated
timing
clinical
trial
readouts
regulatory
submissions
rolling
submission
ema
involves
substantial
risks
uncertainties
could
cause
actual
results
differ
materially
expressed
implied
statements
risks
uncertainties
include
among
things
uncertainties
inherent
research
development
including
ability
meet
anticipated
clinical
endpoints
commencement
completion
dates
clinical
trials
regulatory
submission
dates
regulatory
approval
dates
launch
dates
well
risks
associated
preliminary
data
including
possibility
unfavorable
new
preclinical
clinical
trial
data
analyses
existing
preclinical
clinical
trial
data
may
inconsistent
data
used
selection
vaccine
candidate
dose
level
phase
study
risk
clinical
trial
data
subject
differing
interpretations
assessments
including
peer
review
publication
process
scientific
community
generally
regulatory
authorities
whether
data
mrna
vaccine
program
published
scientific
journal
publications
modifications
whether
regulatory
authorities
satisfied
design
results
future
preclinical
clinical
studies
whether
biologics
license
emergency
use
authorization
applications
may
filed
jurisdictions
potential
vaccine
candidates
whether
applications
may
approved
regulatory
authorities
depend
myriad
factors
including
making
determination
whether
vaccine
candidate
benefits
outweigh
known
risks
determination
vaccine
candidate
efficacy
approved
whether
commercially
successful
decisions
regulatory
authorities
impacting
labeling
manufacturing
processes
safety
matters
could
affect
availability
commercial
potential
vaccine
including
development
products
therapies
companies
manufacturing
capabilities
capacity
including
whether
estimated
numbers
doses
manufactured
within
projected
time
periods
indicated
whether
additional
supply
agreements
reached
uncertainties
regarding
ability
obtain
recommendations
vaccine
technical
committees
public
health
authorities
uncertainties
regarding
commercial
impact
recommendations
competitive
developments
description
risks
uncertainties
found
pfizer
annual
report
form
fiscal
year
ended
december
subsequent
reports
form
including
sections
thereof
captioned
risk
factors
information
factors
may
affect
future
results
well
subsequent
reports
form
filed
securities
exchange
commission
available
biontech
biopharmaceutical
new
technologies
next
generation
immunotherapy
company
pioneering
novel
therapies
cancer
serious
diseases
company
exploits
wide
array
computational
discovery
therapeutic
drug
platforms
rapid
development
novel
biopharmaceuticals
broad
portfolio
oncology
product
candidates
includes
individualized
therapies
innovative
chimeric
antigen
receptor
cells
checkpoint
targeted
cancer
antibodies
small
molecules
based
deep
expertise
mrna
vaccine
development
manufacturing
capabilities
biontech
collaborators
developing
multiple
mrna
vaccine
candidates
range
infectious
diseases
alongside
diverse
oncology
pipeline
biontech
established
broad
set
relationships
multiple
global
pharmaceutical
collaborators
including
genmab
sanofi
bayer
animal
health
genentech
member
roche
group
regeneron
genevant
fosun
pharma
pfizer
information
please
visit
biontech
statements
press
release
contains
statements
biontech
within
meaning
private
securities
litigation
reform
act
statements
may
include
may
limited
statements
concerning
biontech
efforts
combat
collaboration
biontech
pfizer
develop
potential
vaccine
anticipated
timing
clinical
trial
readouts
regulatory
submissions
regulatory
approvals
statements
press
release
based
biontech
current
expectations
beliefs
future
events
subject
number
risks
uncertainties
could
cause
actual
results
differ
materially
adversely
set
forth
implied
statements
risks
uncertainties
include
limited
competition
create
vaccine
ability
produce
comparable
clinical
results
larger
diverse
clinical
trials
ability
effectively
scale
productions
capabilities
potential
difficulties
discussion
risks
uncertainties
see
biontech
annual
report
form
filed
sec
march
available
sec
website
information
press
release
date
release
biontech
undertakes
duty
update
information
unless
required
law
pfizer
contacts
media
relations
andy
widger
investor
relations
chuck
triano
biontech
contacts
media
relations
jasmina
alatovic
media
